Tg4010 Vaccine Targeting on NSCLC
نویسندگان
چکیده
Lung cancer is the most common factor of cancer-related deaths and about 85% of lung cancer is non-small cell lung cancer (NSCLC). MUC1, known as the attached protein or trans-membrane protein, is a kind of protein with highly glycosylation (greater than 50%) and high molecular weight (Mr>200*103). MUC1 is overexpressed in many malignancies, and as a tumor-associated antigens (TAAs), it exposes antigenic epitopes and potential T-cell targets. TG4010 vaccine, which encodes as MUC1 tumorassociated antigen and interleukine-2 and targets MUC1, is an effective and promising targeting strategy for patients with advanced NSCLC when in combination with first-line chemotherapy. This review is mainly aiming to focus on the evidence to clinical statistic data of different phases TIME trails for efficacy of TG4010 vaccine immunotherapy observed in NSCLC and some consequent thoughts.
منابع مشابه
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
BACKGROUND Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone. Our study intended to establish the association between overall survival and vaccine-induced T cell respon...
متن کاملSequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
TG4010, a Modified Vaccinia virus Ankara (MVA) expressing human mucin1 (MUC1) has demonstrated clinical benefit for patients suffering from advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy. To support its development, preclinical experiments were performed with either TG4010 or β-galactosidase-encoding MVA vector (MVA-βgal) in mice presenting tumors in the lung. Tumo...
متن کاملImpact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial
BACKGROUND This study describes the effect of TG4010 vaccine on Health related Quality of Life (HRQOL) in patients with stage IIIb and IV non-small-cell lung cancer (NSCLC). METHODS 148 patients with advanced NSCLC expressing MUC1 were randomly assigned to receive TG4010 plus chemotherapy or chemotherapy alone. HRQOL was assessed with the Functional Assessment of Cancer Therapy-Lung (FACT-L) ...
متن کاملTherapeutic vaccines in non-small cell lung cancer
Non-small cell lung cancer (NSCLC) unfortunately carries a very poor prognosis. Patients usually do not become symptomatic, and therefore do not seek treatment, until the cancer is advanced and it is too late to employ curative treatment options. New therapeutic options are urgently needed for NSCLC, because even current targeted therapies cure very few patients. Active immunotherapy is an opti...
متن کاملTG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial John Nemunaitis, Zsolt Papai, Hervé Léna, Gyorgy Losonczy, Frederic Forget, Christos Chouaid, Alexandra Szczesna, Radj Gervais, Christian H Ottensmeier, Joseph Beck, Andrzej Kazarnowicz, Virginie Westeel, Didier Debieuvre, Anne Madroszyk, Enriqueta F...
متن کامل